A team led by Professor Kazuhiro Maeshima of the National Institute of Genetics (ROIS) and SOKENDAI in Japan has developed a ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Multi-epitope immunopurifications of huntingtin (HTT) from vulnerable brain regions of Huntington’s disease (HD) models ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

When the transatlantic startup AIRNA launched in 2023, it was already years behind other companies that were trying to bring ...

As warehouses go, nuclei are more like libraries than bank vaults. Too many cellular components need access to the genome to lock it down like Fort Knox. Instead, large groupings of more than 1,000 ...

When your social media account starts spewing out nonsensical or threatening status updates, it's safe to assume that it has ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

RNA therapy involves the use of RNA-based molecules to treat or prevent a disease that have been applied to experiments and clinical trials. RNA-based medicines and vaccines such as mRNA, ASOs, siRNA, ...

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

HDAC6 is upregulated in corneal diseases and causes ENKD1 deacetylation at lysine 98. Deacetylation of ENKD1 blocks its ...